Is Vepotolizumab (POLIVY) reimbursed by medical insurance?

Vepotuzumab (POLIVY) is an injectable preparation. The original drug has been launched in China. Due to its short time on the market, it has not yet entered the scope of medical insurance. It is understood that the price of 30mg per box may be around 10,000 yuan, and the Hong Kong version is 140mg. The price of each box may be around RMB 60,000 (the price may fluctuate due to the exchange rate). Vepotolizumab is a new treatment drug for CD79b-positive diffuse large B-cell lymphoma (DLBCL). It is used in combination with other drugs. Since this drug is a controlled drug, its domestic purchase conditions may be difficult.